Loading stock data…
STXS
$1.88-0.02 (-1.05%)
After Hours$1.89+0.01 (+0.54%)· Last close May 11
Stereotaxis, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Stereotaxis, Inc. in the Healthcare sector is trading at $1.88. The stock is currently near its 52-week low of $1.74, remaining 22.6% below its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why STXS maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.88
Potential Upside
5%
Whystock Fair Value$1.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$191.06M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-115.61%
Volume
Today's trading volume
313,475
Recent News
Inogen (INGN) Reports Q1 Loss, Beats Revenue Estimates
Inogen (INGN) delivered earnings and revenue surprises of -25.00% and +3.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Beats Revenue Estimates
Sight Sciences (SGHT) delivered earnings and revenue surprises of +14.30% and +6.06%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Beats Q1 Earnings and Revenue Estimates
Integra (IART) delivered earnings and revenue surprises of +32.78% and +2.74%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Why Stereotaxis (STXS) Could Be One of the Best Robotics Stocks to Buy Under $30
With a street-high upside potential of 159.0%, Stereotaxis, Inc. (NYSE:STXS) ranks among the 10 best robotics stocks to buy under $30. The first time the company’s MAGiC catheter was used in the U.S., it did not ease into things gently. On April 22, 2026, Stereotaxis, Inc. (NYSE:STXS) saw its newly FDA-approved robotic magnetic ablation catheter […]
Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval
STXS stock gains after first U.S. MAGiC procedures, marking a key milestone in robotic cardiac care and boosting its growth outlook.